PrognomIQ has filed a notice of an exempt offering of securities to raise $11,872,784.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, PrognomIQ is raising up to $11,872,784.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About PrognomIQ
PrognomiQ is a company dedicated to transforming the detection and early treatment of cancer and other complex diseases by leveraging multi-omics data. They develop innovative test products through the generation of proprietary proteomic data at unparalleled volumes and depth, which is then complemented with genomic, metabolomic, and other health data. This powerful multi-omics platform provides extensive biological insights, enabling the development of transformative healthcare products with the potential to impact millions of lives. The company aims to unlock earlier treatment for better outcomes, faster therapy response determination, and novel insights for drug discovery and development.
To learn more about PrognomIQ, visit https://prognomiq.com/
PrognomIQ Linkedin Page: https://www.linkedin.com/company/prognomiq-inc/
Contact:
Philip Ma, Chief Executive Officer
650-240-8850
https://www.linkedin.com/in/philip-cm-ma/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.